Category: plos one

In July 2014, Elisabeth Bik notified PLOS ONE that she’d found three papers in the journal by a group of researchers who had clearly manipulated figures in the articles. 

More than six years later, the journal has finally retracted the publications. 

The authors were affiliated with the Fourth Military Medical University in Shaanxi, China. The notice for 2013’s “Hyperthermia-induced NDRG2 upregulation inhibits the invasion of human hepatocellular carcinoma via suppressing ERK1/2 signaling pathway” refers to overlapping data in Figure 1A, similarities between data in Figure 1B and Figure 6C despite the fact that lanes “represent samples exposed to different experimental conditions,” and more:

Continue reading “I do wish that journal editors would not take six years to perform an investigation and to retract.”

A homeopathy journal that Elsevier dropped in the wake of concerns about excessive self-citation appears to have carved out a new niche for itself: self-pity. 

In 2016, Homeopathy lost its slot on Thomson Reuters’s (now Clarivate’s)  influential journal rankings list after an analysis found that more than 70% of citations in the papers it published were of papers it published. That led Elsevier to cut the journal loose — although it remains in business under the umbrella of Thieme, and has since earned its impact factor back. (For more on why that’s important to journals, see this story.)

Part of Homeopathy’s mission under new ownership, it seems, is to criticize journals that have spurned its contributors. Well, one journal, anyway.

Continue reading Did a journal retract your paper on homeopathy? Meet the journal that will publish your complaint

Last month, PLOS ONE published a paper reporting on a trial to improve the uptake of the measles vaccine in Nigeria. The researchers were affiliated with IDinsight, a San Francisco-based “global advisory, data analytics, and research organization that helps development leaders maximize their social impact.”

San Francisco is about 7,800 miles from Lagos, and the list of authors — Sam Brownstone, Alison Connor and Daniel Stein, a former economist at the World Bank — seemed suspiciously devoid of Nigerian names.  

That omission was even more strange given the title of the article: “Improving measles vaccine uptake rates in Nigeria: An RCT evaluating the impact of incentive sizes and reminder calls on vaccine uptake.” Almost immediately after publication, Ejemai Eboreime, a physician and public health worker, pointed out on Twitter the implausibility of the implied claim that no local scientists were involved in a randomized controlled trial covering nine clinics throughout the country — which he alleged also was a violation of local research ethics provisions. 

Continue reading “Consistently unsurprised”: Nigerian vaccine study with no Nigerian authors retracted

The associate vice president for research at Georgia State University and founding director of the university’s Center for Molecular and Translational Medicine has had his tenth paper retracted.

Like the nine previous retractions for Ming-Hui Zou, the work underlying the newly retracted paper in PLOS ONE was performed while Zou was at Oklahoma State University.

The extensive retraction notice for “Activation of the AMP-Activated Protein Kinase (AMPK) by Nitrated Lipids in Endothelial Cells” refers to problems in six of the paper’s figures, including unexpected similarities and likely splicing. It concludes:

Continue reading Associate VP for research at Georgia State is up to 10 retractions

A researcher at the University of Cambridge has had two papers subjected to expressions of concern by the editors of PLOS ONE for image problems.

The expressions of concern for “The Coordination of Cell Growth during Fission Yeast Mating Requires Ras1-GTP Hydrolysis” and “The Role of the RACK1 Ortholog Cpc2p in Modulating Pheromone-Induced Cell Cycle Arrest in Fission Yeast” are extensive. They both refer to multiple “discontinuities,” “similarities,” and other issues.

The common author on the two papers is Graham Ladds, who told Retraction Watch that no other papers would be affected. He said that

Continue reading ‘Exceptionally silly mistakes’: PLOS ONE flags two papers by Cambridge researcher for image issues

More than five years after comments appeared on PubPeer about a 2012 paper in PLoS ONE with a raft of problematic images — and a deceased member of the group whom the corresponding author suggests might have been able to support the validity of the data — the journal has retracted the article.

The article, “Placental expression of CD100, CD72 and CD45 is dysregulated in human miscarriage,” was written by a team of researchers at the Università Politecnica delle Marche, in Ancona, Italy. The first, and corresponding, author of the paper was Teresa Lorenzi, of the school’s Division of Neuroscience and Cell Biology.

The paper has 19 citations, including two in 2019, according to Clarivate Analytics’ Web of Science. The lengthy notice begins with a rundown of 14 questions about three of the paper’s figures. We’ll spare you the entire catalog of ships, but here are a few examples: 

Continue reading Death, retirement, and inability to contact authors leads to retraction of paper first flagged five years ago

A group of dentistry researchers in Japan, whose work on stem cells has been the subject of an institutional investigation, have now lost two papers in PLOS ONE for image problems. 

The authors, from Aichi Gakuin University in Nagoya, were led by Makio Mogi, a medicinal biochemist at the school. Mogi asked for at least one of the retractions. 

The first article, published in 2013, was titled “Matrix metalloproteinase-3 in odontoblastic cells derived from Ips cells: unique proliferation response as odontoblastic cells derived from ES cells.” It has been cited 18 times, according to Clarivate Analytics’ Web of Science. According to the notice: 

Continue reading Stem cell researchers have papers retracted for image manipulation

The leader of an international team of genetics researchers is seething after a journal responded to critical tweets about their paper by issuing an expression of concern. 

The article, “Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease,” was published in PLOS Genetics in early June 2019 by a group led by Carles Vilariño-Güell, of the Department of Medical Genetics at the University of British Columbia in Vancouver.

Less than a week after publication, according to Vilariño-Güell, the journal notified him that: 

Continue reading ‘Science by tweet’ prompts expression of concern, irking authors